{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-009861","form_type":"8-K","ticker":"CRSP","cik":"0001674416","company_name":"CRISPR Therapeutics AG","filed_at":"2023-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.094385+00:00","generated_at":"2026-06-17T15:06:54.298482+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CRISPR Therapeutics licenses CRISPR/Cas9 to Vertex for $100M upfront; eligible for $230M milestones","bullets":["Vertex pays $100M upfront for non-exclusive rights to CRISPR/Cas9 for hypoimmune cell therapies in type 1 diabetes.","CRISPR eligible for up to $230M in research and development milestones plus low-to-mid single-digit royalties.","Vertex's existing T1D programs VX-880 and VX-264 are not included; CRISPR retains ViaCyte collaboration.","Agreement expands existing relationship; Phase 1/2 study of VCTX211 (gene-edited stem cell therapy) is ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-009861","json":"https://secwatch.observer/filing/0000950170-23-009861.json","markdown":"https://secwatch.observer/filing/0000950170-23-009861.md","text":"https://secwatch.observer/filing/0000950170-23-009861.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1674416/000095017023009861/0000950170-23-009861-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1674416/000095017023009861/crsp-20230323.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T15:06:54.298482+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1433985496a69e08b53f3c875d7c5d8a66187300","claim":"CRISPR Therapeutics AG entered into Non-Exclusive License Agreement with Vertex Pharmaceuticals Incorporated valued at $100.0 million (effective 2023-03-23).","evidence_excerpt":"On March 23, 2023, CRISPR Therapeutics AG (“CRISPR”) entered into a Non-Exclusive License Agreement (the “Non-Ex License”) with Vertex Pharmaceuticals Incorporated (“Vertex”), pursuant to which CRISPR agreed to license to Vertex, on a non-exclusive basis, certain of its gene editing intellectual property to exploit certain products for the diagnosis, treatment or prevention of diabetes type 1, diabetes type 2 or insulin dependent/requiring diabetes throughout the world.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1674416/000095017023009861/0000950170-23-009861-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Vertex Pharmaceuticals Incorporated"},{"label":"Value","value":"$100.0 million"},{"label":"Effective","value":"2023-03-23"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}